This report identifies the global exanthema market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global exanthema market.
Geographically North America dominated global exanthema market, and Asia Pacific is projected to have fastest growth, owing to rapidly increasing awareness levels, modernizing healthcare infrastructure, and favourable government support in this region. Chloroamphenicol sodium succinate, tazarotene and threolone are some of the drugs in the investigational phases for treatment of exanthema.
This report segments global exanthema market on the basis of type, and regional market as follows:
Exanthema Market, By Product: Rubeola, Rubella, Erythema Infectiosum, and Roseola Infantum
This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the exanthema market. Some of the major companies’ profiles in detail are as follows:
Manus Aktteva Biopharma LLP
Teva Pharmaceutical Industries Ltd.
CIRON Drugs & Pharmaceuticals Pvt. Ltd.
Iol Chemicals And Pharmaceuticals Limited
Reckitt Benckiser Group plc
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Exanthema Market– Market Forces
4.1.1. Increasing research activities for development of novel therapeutics against viral exanthema symptoms
4.1.2. Rise in susceptibility of infants towards these infections due to weak immune system
4.1.3. Increasing government support
4.2.1. The research and development having higher cost
4.2.2. Lack of standardization
4.2.3. Negligence towards diagnosing the symptoms
4.3.1. Emerging economies
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Exanthema Market, By Type
5.3. Erythema Infectiosum
5.4. Roseola Infantum
6. Exanthema Market, By Geography
6.1.7. Rest of Europe
6.2. Asia Pacific
6.2.4. South Korea
6.2.5. Rest of Asia-Pacific
6.3. North America
6.4. Rest of the World (RoW)
6.4.2. Rest of RoW
7. Exanthema – Market Entropy
7.2. Technological Developments
7.3. Merger & Acquisitions, and Joint Ventures
7.4. Supply- Contract
8. Company Profiles(By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
8.1. Manus Aktteva Biopharma LLP
8.2. Teva Pharmaceutical Industries Ltd.
8.3. CIRON Drugs & Pharmaceuticals Pvt. Ltd.
8.4. Iol Chemicals And Pharmaceuticals Limited
8.5. Reckitt Benckiser Group plc
8.6. Mikart Inc
8.7. Ranbaxy Laboratories Limited
8.8. West-Ward Pharmaceutical Corp.
8.9. Nexgen Pharma, Inc
8.10. Concord Laboratories
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
9.3. Research Methodology
9.4. Expert Insights